Optimal, two-stage, adaptive enrichment designs for randomized trials, using sparse linear programming

被引:6
|
作者
Rosenblum, Michael [1 ]
Fang, Ethan X. [2 ]
Liu, Han [3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Penn State Univ, University Pk, PA 16802 USA
[3] Northwestern Univ, Evanston, IL USA
基金
美国国家科学基金会;
关键词
Adaptive enrichment designs; Decision rules; Multiple testing; Optimization problems; Sparse linear programs; II/III CLINICAL-TRIALS; HYPOTHESES SELECTION; SUBGROUP SELECTION; TARGETED THERAPY; INTERIM; DECISION; SUBPOPULATIONS; POPULATION;
D O I
10.1111/rssb.12366
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
Adaptive enrichment designs involve preplanned rules for modifying enrolment criteria based on accruing data in a randomized trial. We focus on designs where the overall population is partitioned into two predefined subpopulations, e.g. based on a biomarker or risk score measured at baseline. The goal is to learn which populations benefit from an experimental treatment. Two critical components of adaptive enrichment designs are the decision rule for modifying enrolment, and the multiple-testing procedure. We provide a general method for simultaneously optimizing these components for two-stage, adaptive enrichment designs. We minimize the expected sample size under constraints on power and the familywise type I error rate. It is computationally infeasible to solve this optimization problem directly because of its non-convexity. The key to our approach is a novel, discrete representation of this optimization problem as a sparse linear program, which is large but computationally feasible to solve by using modern optimization techniques. We provide an R package that implements our method and is compatible with linear program solvers in several software languages. Our approach produces new, approximately optimal trial designs.
引用
收藏
页码:749 / 772
页数:24
相关论文
共 50 条
  • [1] Optimal planning of adaptive two-stage designs
    Pilz, Maximilian
    Kunzmann, Kevin
    Herrmann, Carolin
    Rauch, Geraldine
    Kieser, Meinhard
    [J]. STATISTICS IN MEDICINE, 2021, 40 (13) : 3196 - 3213
  • [2] Optimal adaptive two-stage designs for early phase II clinical trials
    Shan, Guogen
    Wilding, Gregory E.
    Hutson, Alan D.
    Gerstenberger, Shawn
    [J]. STATISTICS IN MEDICINE, 2016, 35 (08) : 1257 - 1266
  • [3] Optimal adaptive two-stage designs for phase II cancer clinical trials
    Englert, Stefan
    Kieser, Meinhard
    [J]. BIOMETRICAL JOURNAL, 2013, 55 (06) : 955 - 968
  • [4] Optimal Two-Stage Randomized Multinomial Designs for Phase II Oncology Trials
    Sun, Linda Z.
    Chen, Cong
    Patel, Kamlesh
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2009, 19 (03) : 485 - 493
  • [5] Optimal two-stage designs for exploratory basket trials
    Zhou, Heng
    Liu, Fang
    Wu, Cai
    Rubin, Eric H.
    Giranda, Vincent L.
    Chen, Cong
    [J]. CONTEMPORARY CLINICAL TRIALS, 2019, 85
  • [6] TWO-STAGE DESIGNS IN RANDOMIZED PHARMACOGENETIC CLINICAL TRIALS
    Yu, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S79 - S79
  • [7] Optimal Tests of Treatment Effects for the Overall Population and Two Subpopulations in Randomized Trials, Using Sparse Linear Programming
    Rosenblum, Michael
    Liu, Han
    Yen, En-Hsu
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2014, 109 (507) : 1216 - 1228
  • [8] Adaptive two-stage designs in phase II clinical trials
    Banerjee, Anindita
    Tsiatis, Anastasios A.
    [J]. STATISTICS IN MEDICINE, 2006, 25 (19) : 3382 - 3395
  • [9] Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs
    Ballarini, Nicolas M.
    Burnett, Thomas
    Jaki, Thomas
    Jennison, Christoper
    Koenig, Franz
    Posch, Martin
    [J]. STATISTICS IN MEDICINE, 2021, 40 (12) : 2939 - 2956
  • [10] An Efficient Algorithm to Determine the Optimal Two-Stage Randomized Multinomial Designs in Oncology Clinical Trials
    Zhang, Yong
    Mietlowski, William
    Chen, Bee
    Wang, Yibin
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (01) : 56 - 65